About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Liver Diseases group is a referent at the local, national and international level in research, and is one of the most active groups in clinical research at VHIR. The group's prominent involvement in clinical trials is a clear indication of our professionals' commitment to ensuring that patients have access to state-of-the-art therapies. Our participation and collaboration in international projects and consortiums are also a fundamental characteristic of the group. The main objective of the group is to become one of the best translational research groups in liver diseases. It is essential to be able to apply all the findings of basic research to clinical research to improve the health of patients with liver disease.
IP: Maria Buti Ferret Collaborators: Maria del Mar Riveiro Barciela, Judit Romero Vico, Judit Romero Vico, Mª Eulàlia Molinas Guilera, Amaia Latasa Arrazubi Funding agency: EUROPEAN COMMISSION Funding: 211443.8 Reference: IP-CURE-B_H2020SC1BHC2019 Duration: 01/01/2020 - 31/12/2025
IP: Juan Ignacio Esteban Mur Collaborators: Lluís Viladomiu Catà, Silvia Sauleda Oliveras, Jordi Llaneras Artigues, Marta Bes Maijo, Cristina Dopazo Taboada, Angie Rico Blazquez Funding agency: Instituto de Salud Carlos III Funding: 159720 Reference: PI19/00533 Duration: 01/01/2020 - 30/06/2024
IP: Isabel Campos Varela Collaborators: Lluis Castells Fusté, Nuria Roson Gradaille, Ernest Hidalgo Llompart Funding agency: Instituto de Salud Carlos III Funding: 84095 Reference: PI19/00330 Duration: 01/01/2020 - 30/06/2024
IP: Maria Buti Ferret Collaborators: Maria Jose Herrero Mata, Ana Barreira Diaz, Maria del Mar Riveiro Barciela, Jordi Llaneras Artigues, Impact of HLA haplotypes and HDV viremia in developing of clinical events and quality of life of patients with chronic hepatitis Funding agency: Instituto de Salud Carlos III Funding: 117370 Reference: PI20/01692 Duration: 01/01/2021 - 30/06/2025
The CHANCE study analyzes the outcomes of nearly 1,000 patients at 63 liver transplant centers and identifies which patients with the most severe forms of the disease may benefit from transplantation.
The grants support projects led by Drs. María José Buzón, María Buti, Elena Élez, and Maria Vieito.
The grants, amounting to more than €533,000 for VHIR, will allow clinical duties to be partially released over three years to promote strategic research projects in obesity, respiratory diseases, aortic pathology and metabolic fatty liver disease.
